Outlook Therapeutics, Inc.
OTLK
$0.50
-$0.01-1.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -333.56% | -145.38% | 59.44% | 255.46% | 143.81% |
| Total Depreciation and Amortization | 3.13% | 2.44% | 3.19% | 2.13% | 157.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.18% | 109.71% | -62.94% | -1,622.33% | -1,308.94% |
| Change in Net Operating Assets | -22.73% | 222.82% | -369.62% | 264.09% | 312.25% |
| Cash from Operations | 27.12% | 39.01% | 13.93% | 15.84% | -33.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -2,991,718.18% | -- | 100.00% |
| Issuance of Common Stock | -- | 228.55% | -67.50% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10,151.74% | 207.50% | -67.16% | 54,550.00% | -104.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.22% | 108.84% | -94.97% | 29.23% | -65.71% |